摘要
目的探讨西格列汀联合二甲双胍治疗2型糖尿病的临床疗效。方法随机选取2型糖尿病患者46例,随机均分为对照组与观察组(n=23),观察组患者采取西格列汀联合二甲双胍进行治疗,对照组采取吡格列酮联合二甲双胍进行治疗,对比2组患者治疗前后FBG、2 h PG、Hb A1c、BMI等指标的变化情况,以及是否出现不良反应。结果治疗后2组患者的FBG、2 h PG、Hb A1c、BMI等指标均有一定程度降低,尤其是FBG、2 h PG下降较为显著,观察组FBG、2 h PG降低程度显著高于对照组(P<0.05);对照组出现胃肠道反应的患者为8例(34.78%),显著多于观察组的2例(8.70%),2组比较差异具有统计学意义(P<0.05)。结论对2型糖尿病患者采取西格列汀联合二甲双胍治疗,是一种有效安全的治疗方法,应在临床治疗过程中广泛使用。
Objective To evaluate the clinical efficacy of sitagliptin with metformin in treatment of type 2 diabetes.Methods 46 patients with type 2 diabetes were selected as the study objects,then divided them into control group and observation group randomly（n=23）. Sitagliptin combined with metformin was adopted in observation group, and pioglitazone combined with metformin was adopted in control group. Adverse reactions incidence, changes of indexes such as FBG,2hPG,HbA1c,BMI of two groups before and after treatment were compared.Results After treatment, the FBG,2hPG,HbA1c,BMI of two groups had decreased at a certain degree, especially FBG,2hPG was significant, and the decrease degree of FBG,2hPG in observation group was significantly higher than control group（P〈0.05）. Incidence of gastrointestinal reaction in control group were 8 cases （34.78%）,and was significantly more than 2 cases of observation group （8.70%）,the differences between two groups were statistically significant （P〈0.05）.Conclusion For the treatment of type 2 diabetes, sitagliptin combined with melbine is a effective treatment,which should be widely applied in clinic.
出处
《当代医学》
2015年第3期142-143,共2页
Contemporary Medicine
